Randomized, Open-Label, International, Multi-center, Comparative Study of Efficacy and Safety of BCD-148 (JSC BIOCAD, Russia) and Soliris® in Patients With Paroxysmal Nocturnal Hemoglobinuria

Biocad1 site in 1 country28 target enrollmentApril 4, 2019

ConditionsParoxysmal Nocturnal Hemoglobinuria

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Paroxysmal Nocturnal Hemoglobinuria
Sponsor: Biocad
Enrollment: 28
Locations: 1
Primary Endpoint: AUC LDH
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This clinical study is a randomized, open-label, international, multi-center, comparative study of efficacy and safety of BCD-148 and Soliris® in PNH patients.

It is planned to investigate the efficacy, safety, and immunogenicity of one-year eculizumab course in this study.

PNH - Paroxysmal nocturnal hemoglobinuria

Registry

clinicaltrials.gov

Start Date

April 4, 2019

End Date

December 30, 2020

Last Updated

5 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Biocad

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•He/she gave written informed consent.
•Male or female ≥18 and ≤65 years of age.
•PNH diagnosis documented by flow cytometry data at screening .
•PNH granulocyte clone size ≥10% (according to flow cytometry performed at screening).
•Lactate dehydrogenase (LDH) level ≥1.5 times the upper limit of normal (ULN) at screening and at least one of the following symptoms/syndromes: hemoglobinuria, thrombotic complications, transfusion-dependent chronic hemolysis, anemic syndrome, acute kidney injury episodes or chronic kidney disease, pulmonary hypertension, and signs of smooth muscle dystonia (e.g., abdominal pain, dysphagia, erectile dysfunction, and etc.) within three months before informed consent.
•Platelet count ≥30х109/L at screening.
•Absolute count of neutrophil granulocytes ≥0.75х109/L at screening.
•Willingness to undergo vaccination against Neisseria meningitidis during the screening period and at least 14 days before the first administration of an investigational product .
•If immunosuppressive drug products are used, the duration of this therapy should be at least three months by informed consent date.
•The willingness of patients and their sexual partners of childbearing potential to use reliable contraception methods starting from the informed consent, throughout the study, and for four weeks after the last dose of an investigational product. This requirement does not apply to patients who underwent surgical sterilization and women with menopause established more than two years ago. Reliable contraception methods include one barrier method in combination with one of the following: spermicides or an intrauterine device.

Exclusion Criteria

•History of meningococcal infection (either well-documented or according to oral information provided by a patient).
•Other well-documented complement deficiencies (except for those concerning complement component 5).
•History of bone marrow transplantation (either well-documented or according to oral information provided by a patient).
•HIV, hepatitis B, active hepatitis C, and syphilis .
•A patient with newly diagnosed or relapsing aplastic anemia and/or progressive bone marrow failure with indications for allogeneic bone marrow transplantation or combined immunosuppressive therapy within 6 months after informed consent.
•Acute infection (either well-documented and/or according to oral information provided by a patient) within 4 weeks before informed consent and/or during the screening period and/or relapse of chronic disease at the moment of informed consent and/or during the screening period .
•Any other chronic diseases present at the time of the informed consent which can negatively affect the patient's safety during the study, in the Investigator' opinion.
•Use of eculizumab and/other anti-C5 monoclonal antibodies within three months before informed consent .
•Hypersensitivity to any of BCD-148/Soliris® ingredients, murine proteins and other ingredients of these drug products, and to any of meningococcal vaccine ingredients.
•Documented malignancy, except for cured basal cell carcinoma or cervical carcinoma in situ .

Outcomes

Primary Outcomes

AUC LDH

Time Frame: Weeks 5-27

AUC - Area Under Curve of Lactate dehydrogenase

Secondary Outcomes

The proportion of patients with stable Hb level during the maintenance therapy period(Weeks 5-27)
Changes in LDH level over time(week 27, week 52)
Frequency of breakthrough hemolysis episodes(week 27, week 52)
Mean Hb level over the maintenance therapy period(Weeks 5-27)
Change in mean EORTC QLQ-C30 score(week 27, week 52)
The proportion of patients with AE/SAE related to an investigational product, in the Investigator's opinion(week 27, week 52)
The proportion of patients with thrombotic complications(week 27, week 52)
Change in the count of circulating red blood cells with the PNH phenotype RBC(week 27, week 52)
The proportion of patients who required red blood cell transfusion(week 27, week 52)
The proportion of patients who discontinued early due to AE/SAE related to an investigational product, in the Investigator's opinion, by arm(week 27, week 52)
Change in mean FACIT-Fatigue score(week 27, week 52)
The proportion of patients with СТСАЕ v.5.0 Grade 3-4 AE related to an investigational product, in the Investigator's opinion, by arm(week 27, week 52)
The proportion of BAb- and NAb-positive patients.(week 27, week 52)